deltatrials
Completed PHASE3 NCT00002340

A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

A Randomized, Open-Label Trial of High Dose Atovaquone Versus Low Dose Atovaquone Versus Aerosolized Pentamidine for Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With HIV Infection Who Are Intolerant of TMP/SMX

Sponsor: Glaxo Wellcome

Conditions HIV Infections Pneumonia, Pneumocystis Carinii
Interventions Atovaquone Pentamidine isethionate
Updated 5 times since 2017 Last updated: Jun 23, 2005

This PHASE3 trial investigates HIV Infections and Pneumonia, Pneumocystis Carinii and is currently completed. Glaxo Wellcome leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glaxo Wellcome
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cincinnati, United States
  • • Hampton, United States
  • • Maitland, United States
  • • New York, United States
  • • Tampa, United States